FindTrial
Sign In

A study to compare the incidence of hematological toxicities between bone marrow sparing - intensity modulated radiotherapy and conventional intensity modulated radiotherapy in treatment of carcinoma of uterine cervix.

A Prospective randomized study to compare the incidence of hematological toxicities between bone marrow sparing - intensity modulated radiotherapy and conventional intensity modulated radiotherapy in treatment of carcinoma of uterine cervix. - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2024/07/071465
Enrollment
112
Registered
2024-07-29
Start date
Unknown
Completion date
Unknown
Last updated
2024-08-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C539- Malignant neoplasm of cervix uteri, unspecified

Interventions

Intervention1: Pelvic Bone Marrow Sparing Intensity modulated radiotherapy: •Patients will be divided into two groups (arm A and arm B) before start of study by opaque sealed envelope technique. •All

Sponsors

Sri Venkateswara Institute of Medical Sciences
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: •Carcinoma cervix of International Federation of Gynaecologist and Obstetrician (FIGO) Stage IB1 – IVA. •Patients of age group 18 years and older. •Patients with Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2. •Patients with Hb more than 10 g/dl, TC - more than 4000 cells/cu.mm, PLT - more than 1.5 lakh/cu.mm. •Patients who has given approved informed consent.

Exclusion criteria

Exclusion criteria: •Patients with ECOG performance status of 3-4. •Patients with distant metastasis. •Patients with prior EBRT and/or Brachytherapy to pelvis. •Pregnant women and lactating mothers.

Design outcomes

Primary

MeasureTime frame
1.Grades of hematological toxicity by using Radiation Therapy Oncology Group (RTOG) scoring criteria such as •Leukopenia •Neutropenia •Thrombocytopenia •Anemia Timepoint: From the Day 1 of treatment to 6 weeks.—

Secondary

MeasureTime frame
Dosimetry by Dose Volume Histogram (DVH) such as LSS – V10 & mean dose PB – V10, 20, 40 & mean dose LSS marrow – V10, 20, 40 & mean dose PB marrow – V10, 20, 40 & mean dose HIP marrow – V10, 20, 40 & mean dose Timepoint: •On Day 1 of Treatment.—

Countries

India

Contacts

Public ContactDr Pranabandhu Das

Sri Venkateswara Institute of Medical Sciences, Tirupati.

daspranabandhu@gmail.com9948367281

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026